Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

SAN DIEGO--(BUSINESS WIRE)--Oct 17, 2024--

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.

The conference call will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until December 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals Inc.

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241017732118/en/

CONTACT: Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

ir@acadia-pharm.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY NEUROLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL

SOURCE: Acadia Pharmaceuticals Inc.

Copyright Business Wire 2024.